DISCOVER FINANCE

In early August, a deadline approached for the United States to impose new 50% Section 338 tariffs on $ 20 billion worth of Canadian exports. Both countries met for trade negotiations, and it seemed as if a deal was going to occur, with Canadian negotiators frequently traveling to Washington before the August 19th deadline. And the day before the deadline, Trump announced he would postpone tariffs while alluding to the idea that the countries had come to a deal. Both countrie

Novartis may have just lost a drug that analysts thought could generate up to $6 billion a year. On September 4, 2026, Novartis announced that pelacarsen, its experimental cardiovascular drug, failed a major phase 3 trial. The drug was intended to lower lipoprotein(a), a genetically determined risk factor for heart disease that affects roughly one in five people worldwide. This wasn’t just an opportunity for medicine. From a financial perspective, the commercial stakes were

Private credit has exploded into one of Wall Street’s hottest asset classes. But this week, one of its largest funds reminded investors of an important caveat: private investments do not always come with public-market liquidity. On September 3, 2026, Blackstone revealed that investors had requested roughly $4.3 billion in withdrawals from its flagship Blackstone Private Credit Fund, or BRCD, during the third quarter. Although the requests represented 10% of the fund’s outsta

Few drugs have transformed a pharmaceutical company as quickly as GLP-1s have transformed Eli Lilly. In the second quarter of 2026, Eli Lilly reported $23 billion in revenue, which was a whopping 48% increase from the year before. How they did it? Tirzepatide. Tirzepatide is an injectable medication sold under two brand names. Mounjaro for diabetes and Zepbound for obesity. Mounjaro generated $9.9 billion in quarterly sales, while Zepbound added another $4.9 billion. Together

Within 48 hours, two of the most dominant artificial intelligence companies released their brand-new models. Anthropic pushed out Claude Fable 5.1 on September 1, 2026, followed by OpenAI’s release of GPT-6 Astra on September 3, 2026. The two models are the most capable of their predecessors, and both currently sit atop the AI benchmark rankings. However, the more important story may be what their releases mean for where the AI race is heading next. For years, competition rev

Would you take a chance on a drug that is unfinished but could generate billions in future revenue? For the world’s largest pharmaceutical companies, the answer is yes. Rather than discovering a drug from scratch, Big Pharma has increasingly begun licensing and acquiring drugs from smaller biotech companies or outright buying the companies as a whole. However, they aren’t investing in a finished result, but in a set of rights, patents, and pipelines. While you may think they